CY1112828T1 - Ενωσεις αναστολης της μιτωτικης διαδικασιας - Google Patents

Ενωσεις αναστολης της μιτωτικης διαδικασιας

Info

Publication number
CY1112828T1
CY1112828T1 CY20121100518T CY121100518T CY1112828T1 CY 1112828 T1 CY1112828 T1 CY 1112828T1 CY 20121100518 T CY20121100518 T CY 20121100518T CY 121100518 T CY121100518 T CY 121100518T CY 1112828 T1 CY1112828 T1 CY 1112828T1
Authority
CY
Cyprus
Prior art keywords
union
suspending
suspensions
procedures
compounds
Prior art date
Application number
CY20121100518T
Other languages
English (en)
Inventor
Christopher F Claiborne
Todd B Sells
Stephen G Stroud
Original Assignee
Millennium Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112828(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals, Inc. filed Critical Millennium Pharmaceuticals, Inc.
Publication of CY1112828T1 publication Critical patent/CY1112828T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η παρούσα εφεύρεση αφορά ενώσεις του χημικού τύπου (Ι): και μεθόδους για την αντιμετώπιση του καρκίνου. Συγκεκριμένα, η εφεύρεση παρέχει ισχυρούς αναστολείς της κινάσης Aurora Α, φαρμακευτικές συνθέσεις που περιλαμβάνουν τις ενώσεις και μεθόδους για τη χρήση των ενώσεων στην αντιμετώπιση του καρκίνου.
CY20121100518T 2006-11-16 2012-06-06 Ενωσεις αναστολης της μιτωτικης διαδικασιας CY1112828T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85934006P 2006-11-16 2006-11-16
EP07867449A EP2086981B1 (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression

Publications (1)

Publication Number Publication Date
CY1112828T1 true CY1112828T1 (el) 2016-02-10

Family

ID=39315133

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100518T CY1112828T1 (el) 2006-11-16 2012-06-06 Ενωσεις αναστολης της μιτωτικης διαδικασιας

Country Status (35)

Country Link
US (6) US8026246B2 (el)
EP (4) EP2086981B1 (el)
JP (3) JP5102839B2 (el)
KR (2) KR101342014B1 (el)
CN (2) CN101547924B (el)
AR (1) AR064246A1 (el)
AT (1) ATE556076T1 (el)
AU (1) AU2007322046B2 (el)
BR (1) BRPI0718803B8 (el)
CA (1) CA2669680C (el)
CL (1) CL2007003244A1 (el)
CR (3) CR10782A (el)
CY (1) CY1112828T1 (el)
DK (2) DK2086981T3 (el)
EA (1) EA015779B1 (el)
ES (3) ES2528793T3 (el)
GE (1) GEP20125459B (el)
HK (4) HK1134672A1 (el)
HR (2) HRP20120490T1 (el)
IL (1) IL198690A0 (el)
MA (1) MA30988B1 (el)
MX (3) MX348568B (el)
MY (1) MY153243A (el)
NO (1) NO343338B1 (el)
NZ (3) NZ577042A (el)
PH (1) PH12012502057A1 (el)
PL (2) PL2497772T3 (el)
PT (2) PT2497772E (el)
RS (2) RS52313B (el)
SG (2) SG10201503350TA (el)
SI (2) SI2497772T1 (el)
TW (1) TWI401255B (el)
UA (1) UA94129C2 (el)
WO (1) WO2008063525A1 (el)
ZA (1) ZA200903279B (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0511139B8 (pt) 2004-05-14 2021-05-25 Millennium Pharm Inc compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
EP2373657B1 (en) * 2008-12-05 2016-09-14 Millennium Pharmaceuticals, Inc. 5,7-dihydro-6h-pyrimido[5,4-d][1]benzazepin-6-thiones as plk inhibitors
WO2010074724A1 (en) 2008-12-22 2010-07-01 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd20 antibodies
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
RU2012140021A (ru) 2010-02-19 2014-03-27 Миллениум Фармасьютикалз, Инк. КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНИЛ)-5Н-ПИРИМИДО[5,4-d][2]БЕНЗАЗЕПИН-2-ИЛ]АМИНО}-2-МЕТОКСИБЕНЗОАТА НАТРИЯ
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
WO2011161031A1 (en) * 2010-06-22 2011-12-29 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
TW201316991A (zh) * 2011-06-03 2013-05-01 Millennium Pharm Inc Ｍｅｋ抑制劑與奧諾拉（ａｕｒｏｒａ）ａ激酶選擇性抑制劑之組合
US20130303519A1 (en) * 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103772391A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
EP2976086B1 (en) * 2013-03-22 2020-10-14 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
JP6525474B2 (ja) 2013-12-06 2019-06-05 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
JP2018502089A (ja) * 2014-12-23 2018-01-25 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｒａｆ阻害剤及びａｕｒｏｒａキナーゼ阻害剤の組み合わせ
WO2017015316A1 (en) 2015-07-21 2017-01-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
CA2997769A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
EP3347355B1 (en) 2015-09-09 2022-07-13 Icahn School of Medicine at Mount Sinai Heterotricyclic sulfonamides as anti-cancer agents
WO2017146253A1 (ja) 2016-02-26 2017-08-31 公益財団法人がん研究会 Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系
BR112018068565A2 (pt) 2016-03-15 2019-02-12 Oryzon Genomics, S.A. combinações de inibidores de lsd1 para uso no tratamento de tumores sólidos
JP6188986B1 (ja) * 2017-03-23 2017-08-30 株式会社ノエビア 時計遺伝子発現量調整剤及びエラスチン産生促進剤
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
WO2023196959A1 (en) 2022-04-07 2023-10-12 Eli Lilly And Company Process for making a kras g12c inhibitor
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
WO2024006424A1 (en) 2022-06-30 2024-01-04 Eli Lilly And Company Kras g12c inhibitor for treating cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
CA1138863A (en) 1979-02-07 1983-01-04 Norman W. Gilman Benzazepine-derivatives
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EP0888350A1 (en) * 1996-03-08 1999-01-07 Zeneca Limited Azolobenzazepine derivatives as neurologically active agents
EP0946523A1 (en) * 1996-12-23 1999-10-06 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
PL339544A1 (en) * 1997-09-29 2000-12-18 Meiji Seika Kaisha Tricyclic derivatives of thiazolobenzazepin, method of obtaining them antillergic agents
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
AU4841700A (en) 1999-05-12 2000-11-21 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
AU1651201A (en) 1999-12-06 2001-06-18 Ajinomoto Co., Inc. Amidinophenylpyruvic acid derivative
EP1345922B1 (en) 2000-12-21 2006-05-31 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) * 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
BR0211729A (pt) 2001-08-09 2004-08-24 Actelion Pharmaceuticals Ltd Compostos, composições farmacêuticas, processo para fabricar compostos, uso de um ou mais compostos, e, processo para fabricar composições farmacêuticas
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
BRPI0511139B8 (pt) 2004-05-14 2021-05-25 Millennium Pharm Inc compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos
JP2008520713A (ja) 2004-11-17 2008-06-19 ミイカナ セラピューティクス インコーポレイテッド キナーゼ阻害剤
WO2006070198A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
PT1962830E (pt) 2005-12-23 2013-05-29 Glaxosmithkline Llc Inibidores azaindólicos de cinases aurora
WO2008021038A2 (en) 2006-08-09 2008-02-21 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها

Also Published As

Publication number Publication date
RS53788B1 (en) 2015-06-30
TWI401255B (zh) 2013-07-11
US20210214361A1 (en) 2021-07-15
US10836766B2 (en) 2020-11-17
US20080167292A1 (en) 2008-07-10
CR20140544A (es) 2015-01-12
HK1134672A1 (en) 2010-05-07
NZ611898A (en) 2015-01-30
NZ577042A (en) 2012-03-30
JP5452811B2 (ja) 2014-03-26
US9765076B2 (en) 2017-09-19
US20110312942A1 (en) 2011-12-22
EP2497772B1 (en) 2014-10-29
AR064246A1 (es) 2009-03-25
BRPI0718803A2 (pt) 2013-12-03
KR101110458B1 (ko) 2012-03-13
PT2497772E (pt) 2015-02-05
JP2010510215A (ja) 2010-04-02
NO20091864L (no) 2009-06-15
SG10201503350TA (en) 2015-06-29
KR20090091173A (ko) 2009-08-26
GEP20125459B (en) 2012-03-26
ATE556076T1 (de) 2012-05-15
CL2007003244A1 (es) 2008-04-04
MX343391B (es) 2016-11-04
PH12012502057B1 (en) 2015-09-14
KR20110113210A (ko) 2011-10-14
EA200970486A1 (ru) 2009-10-30
NO343338B1 (no) 2019-02-04
JP5102839B2 (ja) 2012-12-19
MA30988B1 (fr) 2009-12-01
BRPI0718803B1 (pt) 2020-11-17
ES2528793T3 (es) 2015-02-12
ZA200903279B (en) 2010-07-28
WO2008063525A1 (en) 2008-05-29
BRPI0718803B8 (pt) 2021-05-25
SI2086981T1 (sl) 2012-12-31
US20110312943A1 (en) 2011-12-22
CN103483343B (zh) 2016-06-01
RS52313B (en) 2012-12-31
EP2497773B1 (en) 2015-02-25
ES2537451T3 (es) 2015-06-08
EP2086981A1 (en) 2009-08-12
PL2086981T3 (pl) 2012-09-28
PH12012502057A1 (en) 2015-09-14
UA94129C2 (ru) 2011-04-11
MY153243A (en) 2015-01-29
PL2497772T3 (pl) 2015-05-29
HK1175777A1 (en) 2013-07-12
ES2384123T3 (es) 2012-06-29
JP2014055166A (ja) 2014-03-27
JP2012006965A (ja) 2012-01-12
HRP20120490T1 (hr) 2012-07-31
IL198690A0 (en) 2010-02-17
DK2497772T3 (en) 2015-01-19
SG176443A1 (en) 2011-12-29
HK1175778A1 (en) 2013-07-12
CA2669680C (en) 2012-04-10
EP2086981B1 (en) 2012-05-02
EP2497773A1 (en) 2012-09-12
MX348568B (es) 2017-06-20
US20190031662A1 (en) 2019-01-31
CA2669680A1 (en) 2008-05-29
US20150166545A1 (en) 2015-06-18
HRP20150047T1 (en) 2015-03-13
CN101547924A (zh) 2009-09-30
EP2944639A1 (en) 2015-11-18
TW200829589A (en) 2008-07-16
SI2497772T1 (sl) 2015-03-31
AU2007322046B2 (en) 2012-04-05
EP2497772A1 (en) 2012-09-12
EA015779B1 (ru) 2011-12-30
EP2944639B1 (en) 2017-01-04
DK2086981T3 (da) 2012-08-06
KR101342014B1 (ko) 2013-12-19
US8026246B2 (en) 2011-09-27
US11958855B2 (en) 2024-04-16
HK1217699A1 (zh) 2017-01-20
AU2007322046A1 (en) 2008-05-29
CN101547924B (zh) 2013-09-25
CN103483343A (zh) 2014-01-01
US9988384B2 (en) 2018-06-05
NZ597252A (en) 2013-06-28
CR20140154A (es) 2014-07-23
CR10782A (es) 2009-06-24
MX2009004670A (es) 2009-05-15
PT2086981E (pt) 2012-06-20

Similar Documents

Publication Publication Date Title
CY1112828T1 (el) Ενωσεις αναστολης της μιτωτικης διαδικασιας
CY1113192T1 (el) Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου μεσω αναστολης της κινασης aurora
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
EA200970156A1 (ru) Пиридизиноновые производные
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
NO20073790L (no) Kjemiske forbindelser
NO20073788L (no) Kjemiske forbindelser
EA201100030A1 (ru) Пиразольные соединения 436
CY1113386T1 (el) Αναστολεις πρωτεασωματος
ME00936B (me) Postupci liječenja kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa
EA200601391A1 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
CY1111197T1 (el) Tριαζολες χρησιμες ως αναστολεις πρετεϊνικων κινασων
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
PL1899329T3 (pl) Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych
EA200870217A1 (ru) 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
EA200970856A1 (ru) Ингибиторы пути хеджхога
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
EA200900135A1 (ru) Производные пиразола в качестве ингибиторов цитохрома р450
CY1113409T1 (el) Αναστολεις ακτ και ρ70 s6 κινασης
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
EA201000613A1 (ru) Тризамещенные пиперидины
CY1117072T1 (el) Ενωσεις αναστολης της μιτωτικης διαδικασιας